126 related articles for article (PubMed ID: 9381987)
1. Development of methotrexate alpha-peptides as prodrugs for activation by enzyme-monoclonal antibody conjugates.
Huennekens FM
Adv Enzyme Regul; 1997; 37():77-92. PubMed ID: 9381987
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.
Vitols KS; Haag-Zeino B; Baer T; Montejano YD; Huennekens FM
Cancer Res; 1995 Feb; 55(3):478-81. PubMed ID: 7834611
[TBL] [Abstract][Full Text] [Related]
3. Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate.
Haenseler E; Esswein A; Vitols KS; Montejano Y; Mueller BM; Reisfeld RA; Huennekens FM
Biochemistry; 1992 Jan; 31(3):891-7. PubMed ID: 1731945
[TBL] [Abstract][Full Text] [Related]
4. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
[TBL] [Abstract][Full Text] [Related]
5. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
6. Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides.
Kuefner U; Lohrmann U; Montejano YD; Vitols KS; Huennekens FM
Biochemistry; 1989 Mar; 28(5):2288-97. PubMed ID: 2719954
[TBL] [Abstract][Full Text] [Related]
7. Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugate.
Esswein A; Hänseler E; Montejano Y; Vitols KS; Huennekens FM
Adv Enzyme Regul; 1991; 31():3-12. PubMed ID: 1877392
[TBL] [Abstract][Full Text] [Related]
8. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs.
Hamstra DA; Pagé M; Maybaum J; Rehemtulla A
Cancer Res; 2000 Feb; 60(3):657-65. PubMed ID: 10676650
[TBL] [Abstract][Full Text] [Related]
9. Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.
Perron MJ; Page M
Br J Cancer; 1996 Feb; 73(3):281-7. PubMed ID: 8562331
[TBL] [Abstract][Full Text] [Related]
10. [The solid-phase synthesis of methotrexate-alpha-peptides].
Shi PT; Hao XK; Chen Y; Zhang YH; Tao QY
Yao Xue Xue Bao; 1997; 32(2):106-9. PubMed ID: 11243192
[TBL] [Abstract][Full Text] [Related]
11. Occurrence and significance of diastereomers of methotrexate alpha-peptides.
Kuefner U; Esswein A; Lohrmann U; Montejano Y; Vitols KS; Huennekens FM
Biochemistry; 1990 Nov; 29(46):10540-5. PubMed ID: 2271663
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
13. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
14. Activation and cytotoxicity of 2-alpha-aminoacyl prodrugs of methotrexate.
Smal MA; Dong Z; Cheung HT; Asano Y; Escoffier L; Costello M; Tattersall MH
Biochem Pharmacol; 1995 Feb; 49(4):567-74. PubMed ID: 7872963
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic potential of methotrexate peptides.
Kuefner U; Lohrmann U; Montejano Y; Vitols KS; Huennekens FM
Adv Enzyme Regul; 1988; 27():3-13. PubMed ID: 3074629
[TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2.
Laethem RM; Blumenkopf TA; Cory M; Elwell L; Moxham CP; Ray PH; Walton LM; Smith GK
Arch Biochem Biophys; 1996 Aug; 332(1):8-18. PubMed ID: 8806703
[TBL] [Abstract][Full Text] [Related]
17. TSPO Ligand-Methotrexate Prodrug Conjugates: Design, Synthesis, and Biological Evaluation.
Laquintana V; Denora N; Cutrignelli A; Perrone M; Iacobazzi RM; Annese C; Lopalco A; Lopedota AA; Franco M
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27322261
[TBL] [Abstract][Full Text] [Related]
18. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
[TBL] [Abstract][Full Text] [Related]
19. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents.
Huennekens FM
Adv Enzyme Regul; 1994; 34():397-419. PubMed ID: 7942284
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate analogues. 13. Chemical and pharmacological studies on amide, hydrazide, and hydroxamic acid derivatives of the glutamate side chain.
Rosowsky A; Yu CS; Uren J; Lazarus H; Wick M
J Med Chem; 1981 May; 24(5):559-67. PubMed ID: 6787199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
